1. Home
  2. NBTX vs SLS Comparison

NBTX vs SLS Comparison

Compare NBTX & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NBTX
  • SLS
  • Stock Information
  • Founded
  • NBTX 2003
  • SLS 2012
  • Country
  • NBTX France
  • SLS United States
  • Employees
  • NBTX N/A
  • SLS N/A
  • Industry
  • NBTX Biotechnology: Pharmaceutical Preparations
  • SLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • NBTX Health Care
  • SLS Health Care
  • Exchange
  • NBTX Nasdaq
  • SLS Nasdaq
  • Market Cap
  • NBTX 211.9M
  • SLS 169.6M
  • IPO Year
  • NBTX 2020
  • SLS N/A
  • Fundamental
  • Price
  • NBTX $6.93
  • SLS $1.64
  • Analyst Decision
  • NBTX Strong Buy
  • SLS Strong Buy
  • Analyst Count
  • NBTX 1
  • SLS 1
  • Target Price
  • NBTX $8.00
  • SLS $7.00
  • AVG Volume (30 Days)
  • NBTX 6.8K
  • SLS 2.7M
  • Earning Date
  • NBTX 09-17-2025
  • SLS 08-12-2025
  • Dividend Yield
  • NBTX N/A
  • SLS N/A
  • EPS Growth
  • NBTX N/A
  • SLS N/A
  • EPS
  • NBTX N/A
  • SLS N/A
  • Revenue
  • NBTX N/A
  • SLS N/A
  • Revenue This Year
  • NBTX N/A
  • SLS N/A
  • Revenue Next Year
  • NBTX $221.06
  • SLS N/A
  • P/E Ratio
  • NBTX N/A
  • SLS N/A
  • Revenue Growth
  • NBTX N/A
  • SLS N/A
  • 52 Week Low
  • NBTX $2.76
  • SLS $0.77
  • 52 Week High
  • NBTX $7.29
  • SLS $2.27
  • Technical
  • Relative Strength Index (RSI)
  • NBTX 71.78
  • SLS 37.88
  • Support Level
  • NBTX $6.49
  • SLS $1.75
  • Resistance Level
  • NBTX $7.15
  • SLS $1.96
  • Average True Range (ATR)
  • NBTX 0.34
  • SLS 0.12
  • MACD
  • NBTX 0.14
  • SLS -0.04
  • Stochastic Oscillator
  • NBTX 84.58
  • SLS 1.13

About NBTX Nanobiotix S.A.

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

About SLS SELLAS Life Sciences Group Inc.

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Share on Social Networks: